Phase III Teriflunomide adjunct therapy with interferon beta

Aubagio is an oral treatment approved for MS.

Phase III Teriflunomide adjunct therapy with interferon beta

Postby MSUK » Tue Oct 26, 2010 1:05 am

Image

Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).

Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical development program. It includes studies of teriflunomide in monotherapy for the treatment of RMS and in clinically isolated syndrome as well as adjunct therapy.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 1981
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Aubagio (teriflunomide)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users